VEA
KURA icon

Virtus ETF Advisers’s Kura Oncology KURA Stock Holding History

Virtus ETF Advisers’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,336
Closed -$63.9K – 625
2024
Q4 		$63.9K Buy
7,336
+3,061
+72% +$44K 0.03% 428
2024
Q3 		$83.5K Buy
4,275
+78
+2% +$1.58K 0.04% 409
2024
Q2 		$86.4K Sell
4,197
-3,057
-42% -$62.8K 0.04% 378
2024
Q1 		$155K Sell
7,254
-493
-6% -$9.58K 0.08% 326
2023
Q4 		$111K Sell
7,747
-877
-10% -$8.62K 0.07% 327
2023
Q3 		$78.7K Sell
8,624
-856
-9% -$8.69K 0.05% 363
2023
Q2 		$100K Buy
9,480
+1,795
+23% +$21.2K 0.06% 378
2023
Q1 		$94K Sell
7,685
-2,950
-28% -$36.8K 0.05% 349
2022
Q4 		$132K Buy
10,635
+2,985
+39% +$43.4K 0.07% 386
2022
Q3 		$104K Buy
7,650
+58
+0.8% +$895 0.04% 417
2022
Q2 		$139K Sell
7,592
-5,009
-40% -$72.1K 0.05% 330
2022
Q1 		$203K Sell
12,601
-753
-6% -$10.9K 0.09% 197
2021
Q4 		$187K Buy
13,354
+4,263
+47% +$69.1K 0.07% 235
2021
Q3 		$170K Sell
9,091
-481
-5% -$9.06K 0.07% 310
2021
Q2 		$200K Buy
9,572
+2,304
+32% +$57.2K 0.08% 347
2021
Q1 		$205K Buy
7,268
+132
+2% +$4.18K 0.09% 326
2020
Q4 		$233K Sell
7,136
-11,771
-62% -$414K 0.1% 328
2020
Q3 		$579K Sell
18,907
-2,572
-12% -$56.8K 0.3% 116
2020
Q2 		$350K Sell
21,479
-2,850
-12% -$41.1K 0.17% 265
2020
Q1 		$242K Sell
24,329
-3,543
-13% -$40.6K 0.1% 258
2019
Q4 		$383K Buy
27,872
+14,306
+105% +$212K 0.06% 274
2019
Q3 		$206K Sell
13,566
-756
-5% -$13.5K 0.04% 244
2019
Q2 		$282K Sell
14,322
-5,119
-26% -$85K 0.06% 243
2019
Q1 		$323K Sell
19,441
-2,529
-12% -$39K 0.69% 54
2018
Q4 		$308K Sell
21,970
-3,468
-14% -$45.9K 0.05% 104
2018
Q3 		$445K Sell
25,438
-18,195
-42% -$349K 0.05% 143
2018
Q2 		$794K Sell
43,633
-11,650
-21% -$197K 0.7% 33
2018
Q1 		$1.04M Buy
55,283
+29,635
+116% +$577K 0.9% 36
2017
Q4 		$392K Buy
+25,648
New +$378K 0.49% 57

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus ETF Advisers's KURA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 7,336 shares — an estimated $63.9K sold.

Virtus ETF Advisers first reported a position in KURA in Q4 2017 and held it in 29 quarters. The position peaked at $1.04M in Q1 2018. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 7,336 Kura Oncology shares in Q1 2025, an estimated $63.9K.
  • Virtus ETF Advisers first reported a position in Kura Oncology in Q4 2017 and held it in 29 quarters.
  • Virtus ETF Advisers's Kura Oncology position peaked at $1.04M in Q1 2018.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.